Novartis Q4 Results
↓
↑
Content
Click below to navigate
through the document
Abbreviations
Company overview
ΑΙ
АІН
aHUS
Financial review
ALL
ALS
Conclusions
AML
Auto-injector
Autoimmune hepatitis
atypical Hemolytic Uremic Syndrome
Acute lymphoblastic leukemia
Amyotrophic lateral sclerosis
Acute myeloid leukemia
IgAN
IgA nephropathy
IPF
ITP
LBCL
BC
Breast cancer
LN
mCRPC
MDS
Appendix
C3G
C3 glomerulopathy
MHSPC
Idiopathic pulmonary fibrosis.
Immune thrombocytopenia
Large B-cell lymphoma
Lupus nephritis
Metastatic castration-resistant prostate cancer
Myelodysplastic syndrome
Metastatic hormone sensitive prostate cancer
CART
Chimeric androgen receptor T
mPDAC
Metastatic pancreatic ductal adenocarcinoma
Innovation: Pipeline overview
CLL
Chronic lymphocytic leukemia
Financial performance
CML
Chronic myeloid leukemia
MS
NASH
Multiple sclerosis
Innovation: Clinical trials
CRC
Colorectal cancer
nmCRPC
Abbreviations
COPD
Chronic obstructive pulmonary disease
COSP
Chronic ocular surface pain
NPR1
nr-axSpA
References
CSU
Chronic spontaneous urticaria
NSAI
CVRR-Lp(a)
CVRR-LDLC
DME
Secondary prevention of cardiovascular events in patients with elevated levels of lipoprotein (a)
Secondary prevention of cardiovascular events in patients with elevated levels of LDLC
Diabetic macular edema
NSCLC
Non-alcoholic steatohepatitis
Non-metastatic castration-resistant prostate cancer
Natriuretic peptide receptor 1
Non-radiographic axial spondyloarthritis
Non-steroidal aromatase inhibitor
Non-small cell lung cancer
OS
Overall survival
PFS
Prefilled syringe
DLBCL
Diffuse large B-cell lymphoma refractory
PNH
Paroxysmal nocturnal haemoglobinuria
ESCC
Esophageal squamous-cell carcinoma
PsA
Psoriatic arthritis
FL
GCA
GVHD
GRPR
HCC
HD
Follicular lymphoma
Giant cell arteritis
Graft-versus-host disease
Hepatocellular carcinoma
Huntington's disease
rHR
Resistant hypertension
rMS
rPFS
Gastrin releasing peptide receptor
SLE
SMA Type 1
HR LBCL
High risk large B-cell lymphoma
ΙΑ
Interim analysis
iAMD
Intermediate age-related macular degeneration
SpA
T1DM
WAIHA
Warm autoimmune hemolytic anemia
SMA Type 2/3
Relapsing multiple sclerosis
Radiographic progression free survival
Systemic lupus erythematosus
Spinal muscular atrophy (IV formulation)
Spinal muscular atrophy (IT formulation)
Spondyloarthritis
Type 1 Diabetes mellitus
IC-MPGN
Immune complex membranoproliferative glomerulonephritis
□ NOVARTIS | Reimagining Medicine.
Novartis Q4 Results | January 31, 2024
85View entire presentation